However, preclinical and clinical evidence supporting this notion is still poor, also due to conflicting results of clinical studies published so far2–9, and which may in part derive from the fact that the prognostic significance of HER2 status has been evaluated in heterogeneous clinical contexts, including patients with different tumor stages, or treated with different types of therapies. The gene discussed is ERBB2; the disease is neoplasm.